News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.
This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September …
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's Silver Upgrade to read this MT …
RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 …
Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and …
Sharemaestro market context Trend signal active 52 weeks +120.8%Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for …
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company …
Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current …
The California State Teachers Retirement System increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% in the first quarter, now holding 26,186 shares valued at $6.76 million. Krystal Biotech reported strong Q1 earnings per share of $1.79, beating analyst estimates, although revenue slightly …
Krystal Biotech (KRYS) reported strong Q2 2026 results, exceeding analyst expectations with robust Vyjuvek sales and expanding market reach. Despite a recent short-term share price dip, longer-term performance remains strong. The article discusses two valuation perspectives: one suggesting the stock is 10.2% undervalued based …
Sharemaestro market context Trend signal active 52 weeks +120.8%Krystal Biotech (KRYS) reported its Q2 2026 earnings, missing both EPS and revenue estimates. Despite the miss, the company highlighted 24% revenue growth for its product VYJUVEK and anticipates several pipeline readouts over the next 12 to 18 months, signaling a potential shift towards …
The Manufacturers Life Insurance Company reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.2% in the first quarter, selling 4,560 shares and retaining 36,069 shares valued at approximately $9.3 million. Despite beating EPS estimates, Krystal Biotech's revenue fell short of analyst forecasts, though …
BofA Global Research has lowered its price objective for Krystal Biotech Inc. (KRYS.O) from $396 to $392. This adjustment reflects a revised outlook from the research firm regarding the biotechnology company. The article provides this key financial update from Reuters.
This article provides a revenue breakdown for Krystal Biotech Inc Unsponsored BDR (K1YS34). It highlights that the company generated 2.14 billion BRL last year, primarily from its Genetic Medicines segment and the United States market. The information is presented within the context of TradingView's …
Krystal Biotech's stock price dropped 8% after its Q1 2026 earnings report, despite solid revenue and profit growth. This decline is attributed to a reset in investor expectations rather than poor financial performance. While the company's gene therapy, VYJUVEK, shows strong gross margins and …
Krystal Biotech (KRYS) shares declined after the company reported second-quarter product revenue of $119.2 million, which missed FactSet estimates of $120.9 million. Despite the revenue miss, the company's Q2 EPS of $1.79 exceeded the FactSet estimate of $1.62. The biotechnology company focuses on genetic …
Krystal Biotech (KRYS) announced strong Q2 2026 financial results, with diluted earnings per share of $1.79, beating the consensus estimate of $1.69. The company reported net income of $54.8 million and generated $119.2 million in revenue, a 24.0% increase year-over-year. This performance reflects increasing …
Krystal Biotech (KRYS) reported its Q2 2026 earnings, missing both EPS and revenue estimates. Despite the miss, the company highlighted 24% revenue growth for its product VYJUVEK and anticipates several pipeline readouts over the next 12 to 18 months, signaling a potential shift towards …
Krystal Biotech (NASDAQ:KRYS) reported Q2 results with adjusted EPS of $1.79, beating analyst estimates, but product revenue of $119.2 million missed the forecast of $122.3 million, causing its stock to fall 7.65% in pre-market trading. Despite the revenue miss, the company's VYJUVEK product showed …
Sharemaestro market context Trend signal active 52 weeks +120.8%Krystal Biotech reported strong second-quarter 2026 results, with revenue reaching $119.22 million and diluted EPS at $1.79, largely driven by increased VYJUVEK sales and successful market expansions. The company achieved significant year-over-year growth in revenue, net income, and EPS, supported by high gross margins …
Krystal Biotech (KRYS) reported strong Q2 2026 earnings, beating the Zacks Consensus Estimate with $1.79 per share and exceeding revenue expectations with $119.22 million. Despite this positive performance and a significant year-to-date stock increase of 38.4%, the company currently holds a Zacks Rank #4 …
Krystal Biotech, Inc. (KRYS) reported Q2 revenue of $119.2 million, falling short of FactSet's estimate of $120.9 million. The company is an integrated, commercial-stage biotechnology firm focused on genetic medicines, with its commercial product VYJUVEK approved for dystrophic epidermolysis bullosa. Analysts currently have a …
Search by ticker symbol or company name and select a result to open its chart.